Molecular Templates to Prioritize Next-Generation ETB Candidates by Carolyn Helms | Apr 5, 2021 | Portfolio News
89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH by Carolyn Helms | Apr 5, 2021 | Portfolio News
Checkmate Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Recent Progress by Carolyn Helms | Mar 29, 2021 | Portfolio News
Nalu Micro-Implantable Pulse Generator Receives Expanded FDA Label for Service Life of 18 Years by Carolyn Helms | Mar 25, 2021 | Portfolio News
